"The U.S. Food and Drug Administration today approved Dotarem (gadoterate meglumine) for use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues of patients ages 2 years and older.
Dotarem is a gadolinium-based"...
- Patient Information:
Details with Side Effects
For those patients being treated for travelers' diarrhea, discontinue XIFAXAN (rifaximin) if diarrhea persists more than 24-48 hours or worsens. Advise the patient to seek medical care for fever and/or blood in the stool [see WARNINGS AND PRECAUTIONS].
Clostridium difficile-Associated Diarrhea
Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN (rifaximin) , and may range in severity from mild diarrhea to fatal colitis. Treatment with antibiotics alters the normal flora of the colon which may lead to C. difficile. Patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If diarrhea occurs after therapy or does not improve or worsens during therapy, advise patients to contact a physician as soon as possible [see WARNINGS AND PRECAUTIONS].
Administration with Food
Inform patients that XIFAXAN (rifaximin) may be taken with or without food.
Counsel patients that antibacterial drugs including XIFAXAN (rifaximin) should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When XIFAXAN (rifaximin) is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by XIFAXAN (rifaximin) or other antibacterial drugs in the future.
Severe Hepatic Impairment
Patients should be informed that in patients with severe hepatic impairment (Child738 Pugh C) there is an increase in systemic exposure to XIFAXAN [see WARNINGS AND PRECAUTIONS].
Last reviewed on RxList: 4/19/2010
This monograph has been modified to include the generic and brand name in many instances.
Additional Xifaxan Information
Xifaxan - User Reviews
Xifaxan User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.